Found a new way to treat depression

Management on sanitary inspection behind quality of foodstuff and medicines USA (FDA) has provided a report on the establishment of a new kind of therapy based on the use in the treatment of patients with clinical depression psychoactive mushrooms. According to the experts, psilocybin therapy for the second time this year was able to prove its effectiveness in the treatment of mental illness and depressive disorders.

According to experts from the United States, psilocybin therapy helps in the treatment of depressive disorders and other diseases of the psyche

Management on sanitary inspection behind quality of foodstuff and medicines USA (FDA) has provided a report on the establishment of a new kind of therapy based on the use in the treatment of patients with clinical depression psychoactive mushrooms. According to the experts, psilocybin therapy for the second time this year was able to prove its effectiveness in the treatment of mental illness and depressive disorders.

Is it possible to cure depression?

As the portal newatlas.com at the end of 2018, the FDA introduced the Pathways COMPASS program as a breakthrough therapy, exploring psilocybin is the key psychoactive compound found in some hallucinogenic mushrooms. So, according to the report of Management on sanitary inspection, a new therapy can help for treatment-resistant to other pharmacological agents type of disease.

As you know, clinical depression is considered to be an acute form of mental illness at which the patient completely loses interest in the world around him and is constantly in a depressed mood, bordering on the emergence of suicidal tendencies. Currently, hundreds of millions of people worldwide suffer from chronic and acute depressive episodes lasting more than two weeks.

Charles Ryson, Director of the Center for clinical and translational research, believes that the introduction into medical practice of methods of treatment of depression based on the use of psilomelane, can be considered truly innovative. Thus, in the framework of the study Usona Phase 2 is planned to cover 80 patients, each of which will be given active dose psilomelane or Niacin — active placebo. After the preparatory therapy, the effect of a single dose of psilomelane will be assessed from the point of view of its impact on other mental illness.

Psilocybin — hallucinogenic mushrooms

Thus, the results of treatment with psilomelane three months showed that after a week, all patients showed a significant decrease in symptoms of depression, and at the end of the experiment five of the twelve volunteers went into stable remission. Despite the fact that an experimental drug had short-term side effects such as confusion of thinking and the emergence of anxiety, it further positive effect is due to the additional stimulation of serotonin receptors 5-HT2A, the activation of which allows the patient to reduce General anxiety and reduce the level of anhedonia.

Research about the possibility of the use of psilocybin for treatment-resistant depression needs to be completed in 2020, when scientists will be able to provide some compelling data about how effective the new psychedelic therapy in the treatment of some forms of prolonged depression.